During the past decade, University of Florida, Department of Neurology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Florida, Department of Neurology" #1 sponsor was "Bial - Portela C S.A." with 1 trials, followed by "Children's Hospital of Philadelphia" with 1 trials sponsored, "Cyberonics, Inc." with 1 trials sponsored, "Eisai Inc." with 1 trials sponsored and "Ipsen" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Florida, Department of Neurology" #1 collaborator was "Friedreich's Ataxia Research Alliance" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Sunovion" with 1 trials as a collaborator and "University of Rochester" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "University of Florida, Department of Neurology" are "Friedreich Ataxia" (2 trials), "Cervical Dystonia" (1 trials), "Epilepsies, Partial" (1 trials), "Epilepsy" (1 trials) and "Neuro-Degenerative Disease" (1 trials). Many other conditions were trialed in "University of Florida, Department of Neurology" in a lesser frequency.

Most popular intervention types in "University of Florida, Department of Neurology" are "Drug" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "1200 mg QD Eslicarbazepine acetate" (1 trials), "800 mg QD Eslicarbazepine acetate" (1 trials), "Botulinum toxin type A" (1 trials) and "Omaveloxolone Capsules, 10 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Florida, Department of Neurology" are 6 trials for "All" genders.

Currently, there are NaN active trials in "University of Florida, Department of Neurology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of Florida, Department of Neurology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Florida, Department of Neurology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".